GSK plc (GSK) on Monday said China's National Medical Products Administration has approved Blenrep in combination with bortezomib and dexamethasone for the treatment of adults with relapsed or refractory Multiple Myeloma who have received at least one prior line of therapy.
The approval is supported by data from the pivotal Phase III DREAMM-7 trial, which showed statistically significant and clinically meaningful improvements in progression-free survival and overall survival for the Blenrep combination compared with a daratumumab-based regimen with bortezomib and dexamethasone.
GSK said the safety and tolerability profile of the Blenrep combination was broadly consistent with the known profiles of the individual medicines.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.